Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

China National Accord Medicines (000028.SZ)

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (Rmb) Price Target (Rmb) Rating
2020-09-1137.7748.846Buy
2021-04-0232.4446.154Buy
2021-08-1727.1541.923Buy
2022-04-0125.4237.769Buy
2022-10-2522.6734.20Buy
2023-06-0642.7746.00Neutral
2023-11-0128.76-No Rating

Disclosures

  • UBS expects to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
  • UBS beneficially owned 1% or more of a class of this company`s common equity securities as of last month`s end (or the prior month`s end if this report is dated less than 10 days after the most recent month`s end).
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day.